China News Service, July 25 (Reporter Chen Jing) The reporter was informed on the 25th that the live broadcast exchange meeting on the diagnosis and treatment progress of childhood leukemia in China disclosed the incidence and diagnosis and treatment status of childhood leukemia in China.
Through the China Child Leukemia Diagnosis and Treatment Registration Management System, 8 provinces were selected as sample provinces in the four geographic regions of East, Central, West and Northeast China for statistical analysis. From 2016 to 2018, the average annual new incidence of leukemia in children aged 0-14 was registered The rate is 42.9 per million. Acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and acute promyelocytic leukemia (APL) are among the top three types of leukemia. Among them, the proportion of acute lymphoblastic leukemia is the highest, reaching 72.4%.
It is understood that in order to understand the overall incidence, diagnosis and treatment and survival conditions of childhood leukemia in China, provide data support for the reasonable setting of designated hospitals for the diagnosis and treatment of childhood leukemia, diagnosis and treatment specifications, and guideline formulation, so as to improve the management of childhood leukemia treatment and improve the health of children , The National Health Commission organized and developed the "China Child Leukemia Diagnosis and Treatment Registration Management System". The registration management system covers a total of 599 designated medical institutions in 31 provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps. So far, more than 39,000 childhood leukemias have been registered.
It is reported that the 5-year overall survival rate and event-free survival rate of children with acute lymphoblastic leukemia are 88.7% and 67.3%, respectively; the 5-year overall survival rate and event-free survival rate of children with acute myeloid leukemia are 74.5% and 46.1%, respectively; The 5-year overall survival rate and event-free survival rate of children with acute promyelocytic leukemia were 93.4% and 89.3%, respectively.
The National Children’s Medical Center and Shanghai Children’s Medical Center affiliated to the Shanghai Jiaotong University School of Medicine told reporters that childhood leukemia is the most common childhood tumor. He pointed out that standardization of diagnosis and treatment can achieve good curative effects without increasing the side effects of treatment and the burden of diagnosis and treatment, thereby comprehensively improving the overall level of diagnosis and treatment of Chinese childhood leukemia.
The Child Leukemia Diagnosis and Treatment Registration Management Center revealed that the next step will be to strengthen the training of full-time or part-time data officers; optimize the database system and further improve the system to better provide solid technical support for improving the level of diagnosis and treatment of Chinese childhood leukemia.
According to reports, multi-center clinical research is the best way to improve the level of diagnosis and treatment. During the interview, the reporter learned that under the guidance of Professor Pei Zhengkang, a foreign academician of the Chinese Academy of Engineering, a number of Chinese institutions have jointly designed and established the China Child Cancer Collaboration Group and the first phase of clinical research. 21 units participated in the clinical multi-center study, with more than 7600 cases enrolled. The various quality control measures adopted by the collaboration group have reduced toxic side effects and treatment-related mortality significantly; the survival rate is also significantly better than the efficacy of the same program outside the collaboration group. According to reports, the collaborative team’s new program and multi-center clinical research have been launched, which will strive to improve disease-free survival. (Finish)